Physician profile
Amy J Munro
NPI 1366447765
$18,358.57
in general payments reported to CMS, 2019-2025
43 companies · $4,475 in 2025
The $4,475 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,599 · 2022: $3,419 · 2023: $3,829 · 2024: $3,036 · 2025: $4,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $22.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,317.25 |
| Education | $22.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,125.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,862.61 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,750.96 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,709.87 | 2021-2025 | |
| Amgen INC. | $1,476.30 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $1,272.71 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,256.81 | 2021-2025 | Xifaxan, Relistor |
| Currax Pharmaceuticals LLC | $926.60 | 2021-2025 | Contrave, Nexlizet, Nexletol |
| Esperion Therapeutics, INC. | $711.02 | 2021-2025 | Nexletol, Nexlizet |
| Exact Sciences Corporation | $564.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $556.11 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.39 | 2021-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $482.48 | 2021-2025 | Veozah, Myrbetriq |
| Corcept Therapeutics | $293.89 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $290.39 | 2021-2024 | Trintellix |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $213.44 | 2021-2024 | |
| Amarin Pharma, INC. | $211.29 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $209.52 | 2021 | |
| Merck Sharp & Dohme LLC | $194.82 | 2021-2023 | Belsomra, Steglatro, Verquvo |
| Axsome Therapeutics, INC. | $191.94 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $154.21 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $132.87 | 2021-2023 | |
| Abbott Laboratories | $126.53 | 2022-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $121.42 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.93 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $105.60 | 2022-2024 | Eliquis, Camzyos |
| Teva Pharmaceuticals USA, INC. | $100.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $85.71 | 2022 | |
| Lundbeck LLC | $77.66 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $74.03 | 2024 | Voquezna |
| Viatris Specialty LLC | $69.45 | 2025 | Yupelri |
| Baxter Healthcare | $64.16 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Eisai INC. | $52.77 | 2021-2022 | |
| Insulet Corporation | $47.33 | 2025 | Omnipod |
| Mylan Specialty L.P. | $46.90 | 2023-2024 | Yupelri |
| Daiichi Sankyo INC. | $39.76 | 2022 | |
| Verona Pharma, INC. | $38.67 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $21.17 | 2025 | Watchman Flx |
| Mannkind Corporation | $20.53 | 2025 | |
| Biocryst US Sales Co., LLC | $18.21 | 2021 | |
| Sumitomo Pharma America, INC. | $17.03 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $16.25 | 2022 | |
| Ibsa Pharma INC. | $14.34 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Munro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.